Inclusion Criteria:  IPF diagnosed, according to 2018 American Thoracic Society (ATS), European Respiratory Society (ERS), Japanese Respiratory Society (JRS), Latin American Thoracic Association (ALAT) IPF guideline for diagnosis and management; Dlco (corrected for Hb): 30%-79% predicted of normal; FVC>= 50% predicted of normal;  Exclusion Criteria:  FEV1/FVC< 0.7; PaO2 in resting state without oxygen inhalation < 50mmHg; Subjects who were likely to be lung transplant recipients or expected to survive less than 1 year during the study period as assessed by the investigator; Poorly controlled cardiovascular and cerebrovascular diseases; Patients who had used nidanib, pirfenidone, interferon, n-acetylcysteine, azathioprine, cyclophosphamide, cyclosporine, prednisone > 15mg/ day (or equivalent dose of other glucocorticoids) within 4 weeks before enrollment; Those who had used Chinese herbal medicine or acupuncture treatment within 1 week before enrollment;